Chimeric NOD2 Mincle Agonists as Vaccine Adjuvants

J Med Chem. 2024 Apr 11;67(7):5373-5390. doi: 10.1021/acs.jmedchem.3c01840. Epub 2024 Mar 20.

Abstract

There is a need for improved vaccine adjuvants to augment vaccine efficacy. One way to address this is by targeting multiple immune cell pathogen recognition receptors (PRRs) using chimeric pathogen-associated molecular patterns (PAMPs). Conjugation of the PAMPs will ensure codelivery of the immunostimulatory molecules to the same cell, enhancing adjuvant activity. The macrophage inducible C-type lectin (Mincle) is a promising PRR for adjuvant development; however, no effective chimeric Mincle adjuvants have been prepared. We addressed this by synthesizing Mincle adjuvant conjugates, MDP-C18Brar and MDP-C18Brar-dilipid, which contain PAMPs recognized by Mincle and the nucleotide-binding oligomerization domain 2 (NOD2). The two PAMPs are joined by a pH-sensitive oxyamine linker which, upon acidification at lysosomal pH, hydrolyzed to release the NOD2 ligands. The conjugates elicited the production of Th1 and Th17 promoting cytokines in vitro, and when using OVA as a model antigen, exhibited enhanced T-cell-mediated immune responses and reduced toxicity in vivo, compared to the coadministration of the adjuvants.

MeSH terms

  • Adjuvants, Immunologic / chemistry
  • Adjuvants, Immunologic / pharmacology
  • Adjuvants, Vaccine*
  • Antigens
  • Cytokines
  • Immunity, Cellular
  • Lectins, C-Type
  • Pathogen-Associated Molecular Pattern Molecules*
  • Receptors, Immunologic

Substances

  • Adjuvants, Vaccine
  • Pathogen-Associated Molecular Pattern Molecules
  • Adjuvants, Immunologic
  • Cytokines
  • Antigens
  • Receptors, Immunologic
  • Lectins, C-Type